Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
Human platelet function as a model for investigating the clinical efficacy of chlorpromazine.
复制标题
人血小板功能作为研究氯丙嗪临床疗效的模型。
DOI：
10.1111/j.1365-2125.1981.tb01262.x
复制
发表时间：
1981
影响因子：
3.4
通讯作者：
B. Oppenheim
中科院分区：
文献类型：
--
作者：
M. Youdim;A. Hefez;B. Oppenheim
1.氯丙嗪（CPZ）可增强部分精神分裂症患者对5-羟色胺（5-HT）的血小板聚集反应（PAR），这可作为评价CPZ疗效的生物学指标。[2]对33例首次精神崩溃后住院的精神分裂症患者进行了双盲临床随访，同时测定了其PAR与5-HT的关系。患者遵循标准化的治疗方案，（CPZ）作为唯一的抗精神病药物。3 12例患者（A组）在2-3周内出现双相5-HT PAR增强，第6周临床症状改善。在大多数情况下，增强的双相PAR的出现先于临床改善。21例患者（B组）在治疗第16周时未出现对5-HT的双相PAR增强。然而，该组中的12名受试者在该阶段结束时显示出对CPZ的临床应答，而其余患者没有改善。4采用Feighner的研究诊断标准时，A组中5-HT的PAR增强最能区分预后良好和不良病例。我们不能证实以前的报告，血小板聚集反应多巴胺在前或后氯丙嗪治疗。
1 Enhancement of platelet aggregation response (PAR) to 5-hydroxytryptamine (5-HT) in some schizophrenic patients receiving chlorpromazine (CPZ) may provide a biological index for the efficacy of this drug. 2 In a double-blind study 33 schizophrenic patients hospitalized following their first psychotic breakdown were followed up clinically with concurrent assessment of their PAR to 5-HT. The patients followed a standardized treatment schedule with (CPZ) as the sole antipsychotic medication. 3 Twelve patients (Group A) developed an enhanced biphasic 5-HT PAR, within 2-3 weeks and improved clinically by the sixth week. In most cases, the appearance of the enhanced biphasic PAR preceded clinical improvement. Twenty-one patients (Group B) did not have enhanced biphasic PAR to 5-HT by the sixteenth week of treatment. However, twelve subjects from this group showed clinical response to CPZ by the end of this period, while the remaining patients did not improve. 4 The enhanced PAR to 5-HT in Group A discriminated best between good and bad outcome cases when Feighner's research diagnostic criteria were used. We could not confirm the previous reports of platelet aggregation response to dopamine in pre- or post-chlorpromazine treatment.